Evidence map›Paper›PMID 39149498›Full record

ArticleResearch square2024

Prototypical innate immune mechanism hijacked by leukemia-initiating mutant stem cells for selective advantage and immune evasion in Ptpn11-associated juvenile myelomonocytic leukemia.

Hong Zheng, Peng Zhao, Zhenya Tan, Wen-Mei Yu, Juwita Werner, Elliot Stieglitz, Chris Porter, Shanmuganathan Chandrakasan, Daniel Wechsler, Simon Mendez-Ferrer and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Hong ZhengDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA; Department of Pathophysiology, Anhui Medical University, Hefei, China.ORCID 0000-0002-4048-6530
Peng ZhaoDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.
Zhenya TanDepartment of Pathophysiology, Anhui Medical University, Hefei, China.
Wen-Mei YuDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.
Juwita WernerDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Elliot StieglitzDepartment of Pediatrics, Division of Pediatric Hematology-Oncology, University of California San Francisco, San Francisco, USA.ORCID 0000-0001-7032-4623
Chris PorterDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.ORCID 0000-0001-8774-0180
Shanmuganathan ChandrakasanDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.ORCID 0000-0001-8007-9932
Daniel WechslerDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.
Simon Mendez-FerrerDepartment of Hematology, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK.
Cheng-Kui QuDepartment of Pediatrics, Aflac Cancer & Blood Disorders Center, Winship Cancer Institute, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, USA.ORCID 0000-0002-4256-8652

Funding

Germline mutations of PTPN11 (SHP2) in the stem cell microenvironmentR01HL130995 · NHLBI · EMORY UNIVERSITY · PI QU, CHENG-KUI · 2016 to 2024
$3.3M
Metabolic regulation of stem cell niche development and functionR01HL162725 · NHLBI · EMORY UNIVERSITY · PI QU, CHENG-KUI · 2022 to 2025
$2.0M
Targeting leukemic stem cells in acute myeloid leukemiaR01CA275964 · NCI · EMORY UNIVERSITY · PI CHENG-KUI QU · 2023 to 2026
$1.7M
NCI NIH HHS R01 CA275964NHLBI NIH HHS R01 HL130995NHLBI NIH HHS R01 HL162725
6 · The paper itself

Abstract

Juvenile myelomonocytic leukemia (JMML), a clonal hematologic malignancy, originates from mutated hematopoietic stem cells (HSCs). The mechanism sustaining the persistence of mutant stem cells, leading to leukemia development, remains elusive. In this study, we conducted comprehensive examination of gene expression profiles, transcriptional factor regulons, and cell compositions/interactions throughout various stages of tumor cell development in Ptpn11 mutation-associated JMML. Our analyses revealed that leukemia-initiating

Indexed as

Hematopoietic stem cellInflammationInnate immunityJMMLLeukemia-initiating cellPTPN11S100a8S100a9

Identifiers

PMID39149498
PMCPMC11326406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.